Glaukos (GKOS) Total Non-Current Liabilities (2014 - 2026)
Glaukos' (GKOS) quarterly Total Non-Current Liabilities came in at $192.9 million in Q1 2026, up 6.62% year-on-year from $180.9 million in Q1 2025, and down 6.17% on a QoQ basis from $205.6 million in Q4 2025.
Glaukos (GKOS) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Glaukos (GKOS) has 13 years of Total Non-Current Liabilities data on file, last reported at $192.9 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 6.62% year-over-year to $192.9 million in Q1 2026; TTM through Mar 2026 was $192.9 million, a 6.62% increase from a year earlier, with the FY2025 full-year figure at $205.6 million, up 10.86% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $192.9 million, down from $205.6 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for GKOS reached as high as $482.6 million in Q1 2024 and fell as low as $180.9 million in Q1 2025.
- Historically, Total Non-Current Liabilities has averaged $338.5 million across 5 years, with a median of $445.2 million in 2022.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 10.86% in 2025 and fell as far as 62.51% in 2025.
- Year by year, Total Non-Current Liabilities stood at $462.1 million in 2022, then grew by 0.61% to $464.9 million in 2023, then plunged by 60.11% to $185.5 million in 2024, then increased by 10.86% to $205.6 million in 2025, then fell by 6.17% to $192.9 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $192.9 million in Q1 2026, $205.6 million in Q4 2025, and $198.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 41.44 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 41.88 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 2.64 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 3.53 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 9.85 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 3.57 Bn |
| 10 | Glaukos | 8.83 Bn | 8.73 Bn | 117.23 Mn | 192.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 192.91 Mn |
| Dec 31, 2025 | 205.59 Mn |
| Sep 30, 2025 | 198.75 Mn |
| Jun 30, 2025 | 191.07 Mn |
| Mar 31, 2025 | 180.93 Mn |
| Dec 31, 2024 | 185.45 Mn |
| Sep 30, 2024 | 235.95 Mn |
| Jun 30, 2024 | 233.84 Mn |
| Mar 31, 2024 | 482.61 Mn |
| Dec 31, 2023 | 464.90 Mn |
| Sep 30, 2023 | 458.18 Mn |
| Jun 30, 2023 | 455.02 Mn |
| Mar 31, 2023 | 452.89 Mn |
| Dec 31, 2022 | 462.10 Mn |
| Sep 30, 2022 | 450.42 Mn |
| Jun 30, 2022 | 459.35 Mn |
| Mar 31, 2022 | 445.18 Mn |
| Dec 31, 2021 | 453.05 Mn |
| Sep 30, 2021 | 454.10 Mn |
| Jun 30, 2021 | 450.82 Mn |